Want to see KURA full AI Analyst Report?
KURA Stock Chart & Stats
$10.39
-$0.06(-0.57%)
At close: 4:00 PM EDT
$10.39
-$0.06(-0.57%)
Day’s Range― - ―
52-Week Range$5.45 - $12.49
Previous CloseN/A
Volume1.14M
Average Volume (3M)1.51M
Market Cap
$799.86M
Enterprise Value$163.85
Total Cash (Recent Filing)$580.82M
Total Debt (Recent Filing)$24.27M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding88,774,370
10 Day Avg. Volume1,083,218
30 Day Avg. Volume1,513,902
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)5.23
Price to Sales (P/S)13.50
P/FCF Ratio-12.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.11Price Target Upside170.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.49
Revenue Forecast (FY)$95.04M
Bulls Say, Bears Say
Bulls Say
Payer Coverage & Formulary PlacementSustained payer coverage above 93% materially reduces reimbursement friction and supports durable patient access. Favorable formulary placement with multiple large plans creates a long‑term commercial foundation that lowers uptake risk and helps sustain prescription volumes as launch expands.
Early Commercial AdoptionRepeat prescriptions, physician switching, and growing patient starts in the first full quarter indicate product‑market fit and effective commercial execution. These durable adoption signals suggest a scalable revenue trajectory as sales infrastructure and account activation continue to expand over the next several quarters.
Cash Runway From Cash + Collaboration PaymentsA large cash balance combined with committed partner payments provides multi‑year runway to support pivotal Phase 3 execution. This structural funding reduces near‑term dilution risk, allows continuation of trials and commercial roll‑out, and supports strategic optionality through readouts and regulatory milestones.
Bears Say
Negative Operating And Free Cash FlowSustained negative operating and free cash flow signals ongoing funding needs and dependency on external capital or partner receipts. If clinical or commercial milestones slip, the company may need to raise capital, increasing dilution risk and pressuring long‑term investment pacing across programs.
Rising R&D And SG&A SpendingMaterial increases in R&D and SG&A reflect heavier investment in combos, pivotal enrollment and commercialization. While strategic, higher structural spend widens losses and raises the steady‑state burn rate, requiring sustained financing or rapid revenue scale to preserve equity value over the medium term.
Dependence On Collaboration ReceiptsSignificant reliance on partner payments creates asymmetric funding risk because recognition is variable and sometimes non‑cash. Delays or variability in collaborator milestones could disrupt planned runway and force reprioritization of programs or external financing, affecting long‑term execution certainty.
Kura Oncology News
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $5.45 and its highest was $12.49 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $799.86M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Oct 29, 2026 which is in 87 days.
How were Kura Oncology’s earnings last quarter?
Currently, no data Available
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 88,774,370 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in KURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kura Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.11 (170.56% Upside)
$28.11 (170.56% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 203.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.5%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.26%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. (KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology therapeutics for the treatment of cancer. The company’s activities center on advancing a pipeline of small-molecule drug candidates through clinical development, with a focus on genetically defined cancers and targeted approaches intended to address specific oncogenic drivers or resistance mechanisms.
KURA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive commercial and clinical outlook: Comzifty's first full quarter produced $5.8M in revenue with strong early adoption signals (85 new patient starts, repeat prescriptions, switching, broad payer coverage >93%, rapid access times). The pipeline is active with multiple near‑term clinical catalysts (EHA, ASCO, multiple combination readouts) and COMMODORE‑17 enrollment is ahead of plan. Offsetting these positives are rising R&D and SG&A spending that widened the net loss (~27.7%), a quarter‑over‑quarter dip in collaboration revenue (~11.4%), and a roughly 13% decrease in cash vs. year‑end 2025. Management expects collaboration payments to extend runway and maintained multi‑year collaboration revenue guidance. Overall, the operational and clinical momentum appears to outweigh the near‑term financial headwinds, though continued execution and monitoring of burn and clinical readouts will be critical.View all KURA earnings summariesKURA Stock 12 Month Forecast
Average Price Target
$28.11
▲(170.56% Upside)
Technical Analysis
Geron
―
CytomX Therapeutics
―
Zentalis Pharmaceuticals
―
Oric Pharmaceuticals
―
Prelude Therapeutics
―
Ownership Overview
2.37% Insiders
10.76% Mutual Funds
3.14% Other Institutional Investors
66.93% Public Companies and Individual Investors